Change of plasma amylin after bariatric surgery challenged by oral glucose is associated with remission of type 2 diabetes mellitus

What Was Tested

Researchers studied Amylin (Islet Amyloid Polypeptide) in this randomized controlled trial publication.

Gastric bypass (GB) and sleeve gastrectomy (SG) were found to achieve different remission rates in the treatment of type 2 diabetes (T2DM).

Nevertheless, amylin, one of the diabetes-associated peptides, so far has an undetermined position on T2DM remission after bariatric surgery.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Sixty eligible patients with T2DM (GB, 30; SG, 30) were initially enrolled in the hospital-based randomized trial.

Twenty patients (GB, 10; SG, 10) who met the inclusion criteria and agreed to undergo 75-g oral glucose tolerance test (OGTT) were recruited.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

The recruited subjects underwent anthropometric measurements, routine laboratory tests, and 75-g OGTT before and 1 year after bariatric surgery.

Enzyme immunoassays for plasma amylin were analyzed.

What Was Measured

Topics PubMed links to this paper include Bariatric Surgery, Diabetes Mellitus, Type 2, Glucose, Islet Amyloid Polypeptide and Remission Induction.

What This Means in Plain Language

The paper is a randomized study of Amylin (Islet Amyloid Polypeptide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Journal of the Chinese Medical Association : JCMA), a journal based in Netherlands.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.